Compare Invesco Preferred ETF (PGX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco Preferred ETF trades at $10.02 (market cap $3.60B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Invesco Preferred ETF is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 94 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PGX | RXRX | |
|---|---|---|
Market Cap | $3.60B | $2.14B |
Volume | 5,986,026 | 30,789,535 |
52-Week High | $11.61 | $6.79 |
52-Week Low | $9.97 | $2.84 |
Typical Hold Time | 94 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.005, up 0.35% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios such as P/E and P/S, and no recent income statement or cash flow data is available. Recent corporate actions include dividend payments scheduled for 2026, but current fundamental metrics are not provided.
The outlook for PGX is cautious due to the absence of current financial data and bearish technical signals. Investment opportunities hinge on future earnings visibility and valuation clarity, while risks include potential earnings volatility and market sentiment shifts. Investors should await updated financial disclosures for a clearer assessment.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
